5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
Key Takeaways
Offer mHSPC combination treatment to men fit to benefit: ADT plus an ARPI, or ADT plus docetaxel plus darolutamide or abiraterone. Discuss triplets particularly in de novo/high-volume disease; ADT alone remains appropriate when combination treatment is unsuitable.
In de novo low-volume mHSPC, prostate radiotherapy improves survival when added to ADT (STAMPEDE Arm H: 55 Gy in 20 daily fractions or 36 Gy in six weekly fractions). Continue appropriate systemic combination treatment.
CRPC requires castrate testosterone < 50 ng/dL (1.7 nmol/L) plus progression: biochemical progression means three consecutive PSA rises at least one week apart, resulting in two 50% increases above nadir and PSA >2 ng/mL; radiological progression includes at least two new bone lesions, ideally confirmed, or RECIST soft-tissue progression.
Non-metastatic CRPC (nmCRPC) with rapid PSA doubling time (PSADT ≤ 10 months) demands the addition of an ARPI (darolutamide, enzalutamide, or apalutamide), which significantly prolongs metastasis-free and overall survival while maintaining continuous background ADT (ARAMIS, PROSPER, SPARTAN).
Select mCRPC treatment by prior therapy, fitness, disease distribution and genomic/PSMA findings. Options include taxanes, suitable ARPIs, PARP inhibitors, 177Lu-PSMA therapy and radium-223. EU olaparib monotherapy after an ARPI requires BRCA1/2 mutation; US rucaparib approval does not establish an EU prostate indication.
5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
The therapeutic landscape of advanced prostate cancer has evolved radically from palliative androgen deprivation monotherapy to multi-agent precision oncology. Contemporary management spans two pivotal clinical disease stages: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and Castration-Resistant Prostate Cancer (CRPC). Candidates for the FEBU examination must master systemic doublet and triplet combinations, landmark trial evidence, the rigorous biochemical and radiographic definitions of castration resistance, and genomic-driven treatment sequencing.
1. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
In men presenting with newly diagnosed metastatic disease (de novo or recurrent after prior definitive local therapy), testosterone suppression remains the backbone of systemic treatment. Offer combination treatment to patients fit to benefit and willing to accept its adverse effects. ADT alone remains appropriate when combinations are contraindicated or unsuitable, including very limited life expectancy.
Primary Androgen Deprivation Therapy
- Mechanism: Depletion of circulating androgens to castrate levels, defined historically as serum total testosterone < 50 ng/dL (1.7 nmol/L), although contemporary assays target < 20 ng/dL (0.7 nmol/L).
- LHRH (GnRH) Agonists: (e.g., goserelin, leuprorelin, triptorelin). Induce an initial surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), producing a temporary "testosterone flare" that can exacerbate spinal cord compression or urinary obstruction. Short-term older-generation AR blockade, commonly bicalutamide 50 mg daily, reduces flare risk but does not eliminate it. For impending cord compression or obstruction, use a GnRH antagonist or orchiectomy for rapid castration rather than relying on flare cover.
- GnRH Antagonists: (e.g., degarelix subcutaneous, relugolix oral). Block pituitary GnRH receptors and suppress testosterone rapidly without an initial surge. Degarelix usually achieves castration by day 3; relugolix achieved castration in 56% by day 4 in HERO. HERO found fewer major cardiovascular events with relugolix than leuprolide; PRONOUNCE ended early, leaving class-wide cardiovascular superiority unresolved.
- Surgical Castration: Bilateral subcapsular orchiectomy provides rapid, permanent castration without flare, but is irreversible.
Modern Systemic Combinations: Doublet & Triplet Regimens
Systemic therapy is stratified by tumor volume using the CHAARTED criteria:
- High-Volume Disease: Presence of visceral metastases (e.g., liver, lung) OR ≥ 4 bone lesions with at least one lesion beyond the vertebral bodies and bony pelvis.
- Low-Volume Disease: Metastatic disease not meeting the high-volume criteria, including nonregional nodal disease without visceral metastases.
- Systemic Doublet Therapy (ADT + ARPI):
- ADT + Abiraterone Acetate / Prednisone: Supported by the LATITUDE and STAMPEDE trials. Abiraterone inhibits CYP17A1 (17α-hydroxylase and 17,20-lyase), suppressing testicular, adrenal, and intracrine tumor androgen biosynthesis. Co-administration of prednisone (5 mg daily in LATITUDE) reduces mineralocorticoid excess (hypertension, hypokalemia, fluid retention).
- ADT + Enzalutamide / Apalutamide: Competitive androgen receptor inhibitors that block androgen binding, AR nuclear translocation, and DNA interaction. Supported by the ARCHES, ENZAMET, and TITAN trials.
- Historical ADT + Docetaxel: CHAARTED tested six cycles of 75 mg/m² without daily prednisone, with survival benefit clearest in high-volume disease. Current EAU recommends docetaxel with an ARPI as a triplet when patients are fit, rather than routinely using the chemotherapy doublet where an ARPI is available.
- Systemic Triplet Therapy (ADT + Docetaxel + ARPI):
- ARASENS Trial: Investigated ADT + docetaxel (6 cycles) + darolutamide (600 mg twice daily). Demonstrated a profound, statistically significant 32% reduction in the risk of death (hazard ratio 0.68) compared to ADT + docetaxel alone in mHSPC; 86% had de novo disease.
- PEACE-1 Trial: Investigated ADT + docetaxel + abiraterone acetate + prednisone. Confirmed an outstanding overall survival benefit in high-volume de novo metastatic patients.
- Guideline Recommendation: Offer docetaxel with ADT plus darolutamide or abiraterone when chemotherapy is selected. Discuss triplet versus ADT–ARPI treatment particularly in de novo/high-volume disease; the pivotal triplet trials did not directly compare triplets with ADT–ARPI doublets.
Local Radiotherapy to the Primary Prostate in mHSPC
The STAMPEDE trial (Arm H) evaluated the role of prostate external beam radiotherapy in newly diagnosed de novo mHSPC:
- In men with low-volume metastatic disease, adding external beam radiation therapy to the primary prostate (e.g., 55 Gy in 20 daily fractions or 36 Gy in 6 weekly fractions) produced a dramatic and statistically significant improvement in 3-year overall survival (81% vs 73%, hazard ratio 0.68).
- In men with high-volume disease, local prostate radiotherapy conferred no survival benefit.
- Guideline Recommendation: Prostate-directed radiotherapy is strongly recommended in patients with newly diagnosed low-volume de novo mHSPC.
2. Castration-Resistant Prostate Cancer (CRPC): Definition & Biology
Resistance commonly involves persistent AR signaling through gene amplification, receptor mutations, constitutively active splice variants (e.g., AR-V7, lacking the ligand-binding domain), or intratumoral steroidogenesis. AR-independent escape mechanisms also occur.
EAU Diagnostic Definition of CRPC
Castration resistance requires documentation of castrate serum testosterone levels accompanied by either biochemical or radiological progression:
- Castrate Serum Testosterone: Confirmed serum total testosterone < 50 ng/dL (1.7 nmol/L).
- PLUS Biochemical Progression: Three consecutive rises in serum PSA, measured at least 1 week apart, resulting in two 50% increases above the nadir, and a PSA > 2.0 ng/mL.
- OR Radiological Progression: The appearance of ≥ 2 new bone lesions on bone scintigraphy, ideally confirmed to exclude flare, OR progression of soft-tissue/visceral lesions according to RECIST 1.1.
Important
When a patient progresses to CRPC, maintain castrate testosterone throughout subsequent treatment, continuing medical ADT unless the patient has had orchiectomy. The trials establishing CRPC therapies maintained androgen suppression.
3. Non-Metastatic CRPC (nmCRPC)
Non-metastatic castration-resistant prostate cancer refers to patients with castrate testosterone levels, rising PSA, and zero evidence of distant metastatic spread on conventional imaging (technetium bone scan and CT chest/abdomen/pelvis).
Risk Stratification & PSA Doubling Time
Patients are risk-stratified by PSA Doubling Time (PSADT):
- High-Risk nmCRPC: PSADT ≤ 10 months. These patients have a high risk of developing rapid bone metastases and cancer-specific mortality.
- Low-Risk nmCRPC: PSADT > 10 months. Monitor serial PSA and arrange imaging according to PSA level/kinetics and symptoms rather than relying only on a fixed calendar interval.
Landmark Trials in High-Risk nmCRPC
Three landmark prospective Phase III trials evaluated second-generation androgen receptor antagonists added to continuous background ADT in men with nmCRPC and PSADT ≤ 10 months:
- ARAMIS Trial (Darolutamide): Darolutamide possesses a unique molecular structure with low blood-brain barrier penetration, with low rates of CNS adverse effects in ARAMIS; falls, fractures and cognitive disorders were similar to placebo. Extended metastasis-free survival (MFS) by 22 months and significantly improved overall survival.
- SPARTAN Trial (Apalutamide): Extended median MFS to 40.5 months vs 16.2 months for placebo. Associated with rash (24%), fatigue, and hypothyroidism.
- PROSPER Trial (Enzalutamide): Extended median MFS to 36.6 months vs 14.7 months for placebo. Associated with hypertension, fatigue, and rare seizure risk.
4. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Treatment of mCRPC is guided by prior therapy (e.g., prior exposure to docetaxel or ARPIs in the hormone-sensitive setting), performance status, metastatic distribution, and genomic biomarkers.
Precision Medicine & Therapeutic Armamentarium
- Secondary Androgen Receptor Pathway Inhibitors (ARPIs):
- Abiraterone acetate (1,000 mg daily + prednisone 5 mg BID) or Enzalutamide (160 mg daily). Indicated in both chemotherapy-naïve and post-docetaxel mCRPC (COU-AA-301/302, AFFIRM, PREVAIL trials). Cross-resistance is frequent and activity is sequence-dependent; routine ARPI-to-ARPI switching is generally discouraged, particularly after a short response, when another effective class is suitable.
- Cytotoxic Taxane Chemotherapy:
- Docetaxel (75 mg/m² IV every 3 weeks + prednisone 5 mg BID): The historical benchmark (TAX 327 trial), improving overall survival, pain, and quality of life.
- Cabazitaxel (20 to 25 mg/m² IV every 3 weeks + prednisone): A semi-synthetic taxane engineered to overcome P-glycoprotein-mediated multi-drug resistance. In the CARD trial, cabazitaxel was randomized against a second ARPI (abiraterone or enzalutamide) in patients with mCRPC who had previously received docetaxel and progressed within 12 months on the alternative ARPI. Cabazitaxel improved median radiographic PFS (8.0 versus 3.7 months) and overall survival (13.6 versus 11.0 months).
- PARP Inhibitors for Homologous Recombination Repair (HRR) Defects:
- Approximately 20% to 25% of men with mCRPC harbor deleterious alterations in DNA repair genes (including BRCA2, ATM, BRCA1, CDK12 and CHEK2).
- Olaparib: Poly(ADP-ribose) polymerase inhibitor. In the PROfound trial, olaparib significantly improved radiographic PFS (7.4 vs 3.6 months) and overall survival (19.1 vs 14.7 months) in the pooled BRCA1/BRCA2/ATM cohort after enzalutamide or abiraterone. This does not establish equal benefit for each gene. EU olaparib monotherapy is licensed for BRCA1/2-mutated mCRPC after a new hormonal agent, not ATM alteration alone.
- Rucaparib: US FDA regular approval (December 2025) covers deleterious germline/somatic BRCA-mutated mCRPC after AR-directed therapy, following TRITON2/3 evidence. Rucaparib has no current EU prostate indication; its EMA indications are ovarian-related cancers.
- Genomic Testing: Offer early somatic testing for HRR and MMR defects in metastatic disease. Germline testing, including BRCA1/2, ATM and MMR genes, is recommended with appropriate counselling; mutation status and local approvals guide drug selection.
- Radioligand Therapy (177Lu-PSMA-617):
- Targeted beta-emitting radiopharmaceutical delivering localized radiation to PSMA-expressing tumor cells. In the VISION trial, Lutetium-177-PSMA-617 (7.4 GBq every 6 weeks for up to 6 cycles) added to standard care significantly prolonged radiographic PFS and overall survival (15.3 vs 11.3 months) in heavily pre-treated men with PSMA-positive mCRPC who had progressed following both an ARPI and at least one taxane regimen.
- Bone-Targeted Therapies & Radiopharmaceuticals:
- Prevention of Skeletal-Related Events (SREs): In bone-metastatic mCRPC, denosumab (120 mg SC monthly) targets RANKL; zoledronic acid (4 mg IV monthly, adjusted for renal function) is an alternative. These reduce pathological fractures, spinal cord compression, and orthopedic interventions. Give calcium/vitamin D, monitor serum calcium, and arrange baseline dental assessment to mitigate the risk of osteonecrosis of the jaw (ONJ).
- Radium-223 Dichloride: An alpha-emitting radiopharmaceutical targeting areas of osteoblastic bone turnover. In the ALSYMPCA trial, Radium-223 (55 kBq/kg IV every 4 weeks for 6 cycles) improved overall survival and delayed symptomatic skeletal events in symptomatic bone-metastatic mCRPC without visceral metastases. Current EU labeling restricts use to after at least two prior mCRPC systemic lines (other than LHRH therapy), or when available systemic treatments are unsuitable. EAU 2026 also recommends enzalutamide–radium with bone protection in selected asymptomatic/mildly symptomatic bone-metastatic patients without visceral disease; that combination is outside the current EU label.
- Safety Warning (ERA 223 Trial): Combining Radium-223 with abiraterone acetate plus prednisone is strictly contraindicated due to an increased incidence of severe skeletal fractures and mortality.
5. Advanced Prostate Cancer Systemic Therapy Matrix
| Disease State | Clinical Features / Biomarkers | Standard Frontline Treatment | Landmark Pivotal Trials | Critical Toxicities & Clinical Pearls |
|---|---|---|---|---|
| mHSPC (De novo, High Volume) | Visceral metastases OR ≥ 4 bone lesions (≥ 1 outside spine/pelvis) | Triplet Therapy: ADT + Docetaxel + Darolutamide (or Abiraterone) | ARASENS, PEACE-1 | Triplet therapy provides substantial OS benefit; monitor neutropenia, fluid retention, transaminases. |
| mHSPC (De novo, Low Volume) | Does not meet CHAARTED high-volume criteria; no visceral spread | Doublet Therapy: ADT + ARPI PLUS Prostate Radiotherapy | STAMPEDE (Arm H), TITAN, ARCHES | STAMPEDE showed an 8-percentage-point three-year OS gain in its low-burden subgroup. Systemic intensification depends on disease timing, fitness and expected benefit. |
| nmCRPC (High Risk) | Castrate testosterone, rising PSA, conventional imaging negative, PSADT ≤10 months | Maintain ADT + Darolutamide, Enzalutamide, or Apalutamide | ARAMIS, SPARTAN, PROSPER | Darolutamide has low CNS penetration; ARAMIS fall/fracture rates resembled placebo. Continue ADT. |
| mCRPC (Post-Docetaxel & Post-ARPI) | Progressive bone/visceral disease; prior docetaxel + ARPI exposure | Cabazitaxel (20–25 mg/m²) + Prednisone | CARD, TROPIC | CARD favoured cabazitaxel over ARPI switching after docetaxel and progression within 12 months on an ARPI. Use G-CSF prophylaxis; consider genomic/PSMA-directed alternatives. |
| mCRPC (BRCA1/2 Mutation, Post-ARPI) | Confirm deleterious germline/somatic BRCA1/2 alteration | Olaparib 300 mg BID (EU monotherapy indication) | PROfound | Anemia, nausea and fatigue; ATM alone does not meet this EU indication. Rucaparib is a US BRCA option, not EU prostate-licensed. |
| mCRPC (PSMA+ on PET, Post-Taxane & ARPI) | PSMA-avid lesions on diagnostic PSMA PET, adequate organ function | 177Lu-PSMA-617 (7.4 GBq q6w, up to 6 cycles) | VISION | Primary toxicities include dry mouth (xerostomia), myelosuppression (thrombocytopenia/anemia), renal impairment. |
| mCRPC (Symptomatic Bone Metastases, No Visceral) | EU label: ≥ 2 prior mCRPC systemic lines, or unsuitable for available systemic therapies | Radium-223 (six injections q4w), with bone protection | ALSYMPCA | Alpha-emitter; abiraterone/prednisone combination contraindicated. Distinguish EU label from newer EAU enzalutamide-combination recommendation. |
A 62-year-old previously healthy man presents with de novo metastatic prostate cancer. Staging CT of the abdomen/pelvis and 99mTc-bone scintigraphy demonstrate 5 osteoblastic bone metastases (two in the lumbar spine, one in the sacrum, one in the right intertrochanteric femur, and one in the left 6th rib). No visceral or liver metastases are present. Baseline PSA is 145 ng/mL, and serum testosterone is normal. According to CHAARTED definitions and modern EAU guidelines, what is the optimal systemic therapeutic management?
Initiate LHRH agonist monotherapy with 4 weeks of oral bicalutamide flare coverage
Perform immediate bilateral radical orchiectomy followed by observation until PSA progression
Initiate triplet systemic therapy consisting of androgen deprivation therapy plus 6 cycles of docetaxel chemotherapy plus darolutamide
Administer 6 cycles of radium-223 dichloride combined with continuous abiraterone and prednisone
A 71-year-old man with metastatic castration-resistant prostate cancer has experienced disease progression with 3 new painful bone lesions and rising PSA despite continuous ADT and upfront abiraterone acetate. His serum testosterone is 16 ng/dL. He subsequently completed 6 cycles of docetaxel chemotherapy 6 months ago. Next-generation sequencing of a fresh metastatic bone biopsy confirms an inactivating, deleterious BRCA2 frameshift mutation. Which targeted therapeutic agent is indicated according to the PROfound trial and EAU guidelines?
Switch secondary hormonal therapy to oral enzalutamide 160 mg daily
Initiate olaparib 300 mg orally twice daily while maintaining background ADT
Administer single-agent bicalutamide 150 mg daily
Commence subcutaneous denosumab 60 mg every 6 months as monotherapy
A 69-year-old man receiving continuous LHRH agonist therapy for non-metastatic prostate cancer presents with a rising PSA. At successive three-month visits over nine months, his PSA increases from 1.2 to 2.4 to 4.8 to 9.6 ng/mL (PSA doubling time = 3.0 months). His serum testosterone is confirmed at 14 ng/dL. Contrast-enhanced CT of the chest, abdomen, and pelvis and 99mTc-bone scintigraphy demonstrate no evidence of nodal, visceral, or skeletal metastasis. What is the standard evidence-based management according to EAU guidelines?
Discontinue the LHRH agonist immediately because the patient has developed castrate-resistant disease
Initiate radium-223 dichloride infusions every 4 weeks for 6 cycles
Initiate systemic taxane chemotherapy with docetaxel 75 mg/m² every 3 weeks
Maintain continuous ADT and add an androgen receptor pathway inhibitor such as darolutamide, apalutamide, or enzalutamide
Sections you finish are checked off in the contents.